Reduced tissue sodium content is related to improvement of vascular function in patients with chronic heart failure treated with the SGLT2 inhibitor empagliflozin

Kolwelter J, Kannenkeril D, Linz P, Jung S, Nagel AM, Bosch A, Ott C, Bramlage P, Uder M, Achenbach S, Schmieder R (2021)

Publication Type: Conference contribution

Publication year: 2021

Journal

European Heart Journal Oxford University Press

Publisher: OXFORD UNIV PRESS

City/Town: OXFORD

Pages Range: 795-795

Conference Proceedings Title: EUROPEAN HEART JOURNAL

DOI: 10.1093/eurheartj/ehab724.0795

Authors with CRIS profile

Julie Kolwelter Department of Medicine 2 – Cardiology and Angiology Peter Linz Institute of Radiology Armin Michael Nagel Professur für metabolische und funktionelle MR-Bildgebung Agnes Bosch Department of Medicine 4 – Nephrology and Hypertension Christian Ott Department of Medicine 4 – Nephrology and Hypertension Michael Uder Lehrstuhl für Diagnostische Radiologie Stephan Achenbach Lehrstuhl für Innere Medizin II Roland Schmieder Professur für Innere Medizin (Nephrologie)

Involved external institutions

Institut für Pharmakologie und präventive Medizin (IPPMed GmbH)

Germany (DE)

How to cite

APA:

Kolwelter, J., Kannenkeril, D., Linz, P., Jung, S., Nagel, A.M., Bosch, A.,... Schmieder, R. (2021). Reduced tissue sodium content is related to improvement of vascular function in patients with chronic heart failure treated with the SGLT2 inhibitor empagliflozin. In EUROPEAN HEART JOURNAL (pp. 795-795). OXFORD: OXFORD UNIV PRESS.

MLA:

Kolwelter, Julie, et al. "Reduced tissue sodium content is related to improvement of vascular function in patients with chronic heart failure treated with the SGLT2 inhibitor empagliflozin." Proceedings of the EUROPEAN HEART JOURNAL OXFORD: OXFORD UNIV PRESS, 2021. 795-795.

BibTeX: Download